PlasmaGen BioSciences

PlasmaGen Biosciences Pvt. Ltd. , based in India, is engaged in the development and distribution of plasma-derived products, focusing on critical medical needs across global markets. PlasmaGen Biosciences Pvt.

Ltd. specializes in manufacturing plasma-derived therapeutics. Founded in 2010 and headquartered in Bangalore, India, the company has undergone strategic developments leading to three total deals to date. Its latest funding round occurred in December 2025, securing INR 1.

5 billion from ViNS Bioproducts, reinforcing its commitment to enhancing global distribution and product offerings. The founder's history is not detailed, nor are there mentions of subsidiaries or parent companies. PlasmaGen specializes in the development and distribution of innovative plasma-derived products and services aimed at addressing critical medical needs. Their core offerings include a range of immunoglobulins, clotting factors, and albumin, all manufactured through advanced purification and fractionation techniques from human plasma.

These products are designed to treat various conditions, such as immune deficiencies, bleeding disorders, and critical care situations, providing essential therapies to healthcare providers worldwide. PlasmaGen's products are utilized by hospitals, clinics, and specialty pharmacies, primarily serving markets in North America, Europe, and parts of Asia, where there is a significant demand for high-quality plasma therapies. PlasmaGen generated revenue of INR 11,371,566. 40 in the most recent year, 2024.

The company's structured B2B model primarily partners with healthcare institutions, distributors, and wholesalers to deliver its plasma products. These transactions typically involve direct sales agreements for bulk purchases and may also include service agreements for ongoing supply and support. PlasmaGen's pricing structure is consistent with market standards and based on contractual agreements, driving steady revenue while fulfilling critical healthcare needs. In December 2025, PlasmaGen Biosciences Pvt.

Ltd. secured INR 1. 5 billion in venture funding led by ViNS Bioproducts, aimed at facilitating the company's growth strategies. The funding will be utilized to expand into international markets, strengthen distribution through new export partners, and enhance its portfolio of plasma-derived therapeutics in India.

Specific plans include the launch of new products designed to cater to emerging medical needs and entering additional geographic markets to further extend its reach.